Normunity
Normunity raises $75M Series B at $500M valuation
Quick Facts
Normunity: Series B Funding Round
Normunity has successfully raised $75M in Series B funding, reaching a valuation of $500M.
Company Overview
T cell engager therapies
Funding Details
The Series B round was led by Samsara BioCapital, with participation from Enavate Sciences, Regeneron Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Employees: 80+
- Category: HealthTech
Investment
Normunity plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Samsara BioCapital: Verified investor in Series B
- Enavate Sciences: Verified investor in Series B
- Regeneron Ventures: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
